BioCentury
ARTICLE | Deals

May 27 Quick Takes: EMDAC votes narrowly in favor of Provention’s teplizumab; plus BMS, Biohaven, Day One, Frazier, miRecule, Oisin and more

May 28, 2021 1:22 AM GMT
Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article